← Association for Accessible Medicines
FDANonrulemakingFDA-2018-D-1041

Development of a Shared System Risk Evaluation and Mitigation Strategy

RIN
—
Last modified
Mar 25, 2021
Comment window
closed 2262d ago
Association for Accessible Medicines filings
3

Activity

Association for Accessible Medicines filed 3 comments on this docket between Aug 3, 2018 and Mar 25, 2021. 5 other organizations filed here. The comment window closed 2262d ago.

What Association for Accessible Medicines filed (3)

Mar 25, 2021· Comment from The Association for Accessible Medicines (AAM)· FDA-2018-D-1041-0024

Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding docket No. FDA-2018-D-1041: Draft Guidance for Industry Development of a Shared Systems REMS. Order of submission is as follows: •Cover letter to FDA •RPA template •Summary of RPA •CDA Template

View on regulations.gov →
May 19, 2020· Comment from The Association for Accessible Medicines (AAM)· FDA-2018-D-1041-0023

Comments from The Association for Accessible Medicines (AAM) on behalf of our member companies, regarding FDA-2018-D-1041: Draft Guidance for Industry; Development of a Shared System Risk Evaluation and Mitigation Strategy.

View on regulations.gov →
Aug 3, 2018· Comment from Association for Accessible Medicines (AAM)· FDA-2018-D-1041-0006

Filed on regulations.gov — full text not in the inline record.

View on regulations.gov →

Abstract

No abstract recorded.

View on regulations.gov →

Co-filers (5)

See everyone who commented →